GGrantIndex
Sort

172,184 grants matching inflammation

Defining the role of IL-18 in atopic dermatitis

$809,010
Steven Van Dyken · Washington University · R01 · FY2024 · AI

Defining the role of IL-18 in atopic dermatitis

$809,010
Steven Van Dyken · Washington University · R01 · FY2025 · AI

Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension

$809,000
Joe G. N. Garcia · Aqualung Therapeutics Corp. · R42 · FY2023 · HL

Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension

$808,999
Joe G. N. Garcia · Aqualung Therapeutics Corp. · R42 · FY2024 · HL

Mechanisms of Asthma-Dietary Interventions against Environmental Triggers

$808,934
Gregory B Diette · Johns Hopkins University · P01 · FY2010 · ES

Innate immune responses to tissue infection by intestinal fungi inhibit wound repair

$808,926
Thaddeus S Stappenbeck · Cleveland Clinic Lerner Com-Cwru · R01 · FY2024 · AI

RNA modification and innate immune activation in HIV infection

$808,844
Hisashi Akiyama · Boston University Medical Campus · R01 · FY2025 · AI

Pathophysiology of Metabolically Detrimental Changes in Adipose Distribution, Adipocyte Function, and Adipose Immune Environment on Antiretroviral Therapy

$808,810
John Koethe · Vanderbilt University Medical Center · R01 · FY2024 · DK

Molecular Chemiluminescence Probes for Imaging of Amyloid beta in Animal Models

$808,786
Chongzhao Ran · Massachusetts General Hospital · R01 · FY2025 · AG

Molecular effects of cannabinoids on the Blood Brain Barrier in HIV-infected brain

$808,747
Maria Cecilia Garibaldi Marcondes · San Diego Biomedical Research Institute · R01 · FY2025 · DA

Mediators of Systemic Inflammation and Heart Failure Risk in the Community

$808,739
Susan Cheng · Cedars-Sinai Medical Center · R01 · FY2022 · HL

Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life

$808,711
Jordana B. Cohen · University Of Pennsylvania · R01 · FY2022 · AG

Lead optimization of novel ML-IAP antagonists to treat lung cancer

$808,701
Nicholas David Cosford · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2016 · CA

Multi Parametric Total-Body Imaging of Immune Activation in Post Acute Sequelae of SARS-CoV-2 (PASC)

$808,672
Negar Omidvari · University Of California At Davis · R01 · FY2025 · AI

BONE MARROW MICROENVIRONMENT AND NEUROBLASTOMA PROGRESSION

$808,641
Yves Declerck · Children'S Hospital Of Los Angeles · P01 · FY2010 · CA

Project 2

$808,557
Jeroen Roose · University Of California, San Francisco · P01 · FY2019 · AI

Regulation of Vascular Integrity

$808,486
Brant Weinstein · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2025 · HD

Mechanisms of innate immune dysfunction in SIV/malaria co-infection in pregnancy

$808,466
Jennifer Manuzak · Tulane University Of Louisiana · R01 · FY2023 · HD

New therapeutics for Shiga toxin-E. coli disease.

$808,403
Fumiko Obata · University Of Maryland Baltimore · U01 · FY2011 · AI

Single-cell Analysis of Normal and Perturbed Dynamic and Spatial Biological Systems

$808,391
Benedict Anchang · National Institute Of Environmental Health Sciences · ZIA · FY2025 · ES

Center for Novel Therapeutics for HIV-Associated Cognitive Disorders

$808,353
Justin C McArthur · Johns Hopkins University · P30 · FY2016 · MH

Biophysical detection of skin changes to cue pressure injury prevention in nursing homes

$808,318
Barbara M. Bates-Jensen · University Of California Los Angeles · R01 · FY2022 · NR

Comprehensive Genome Interrogation of African American Sarcoidosis Families

$808,316
Courtney Montgomery · Oklahoma Medical Research Foundation · R01 · FY2016 · HL

3/9- Predictors and Mechanisms of Conversion to Psychosis

$808,262
Larry J Seidman · Beth Israel Deaconess Medical Center · U01 · FY2014 · MH

Training Program in Lung Biology and Pathobiology

$808,253
Dolly Mehta · University Of Illinois At Chicago · T32 · FY2022 · HL